Trimel Pharmaceuticals Corporation Announces Appointment of New Director

Trimel Pharmaceuticals Corporation Announces Appointment of New Director 
TORONTO, ONTARIO -- (Marketwired) -- 11/27/13 -- Trimel
Pharmaceuticals Corporation (TSX:TRL) today announced the appointment
of Mr. Matthew Pfeffer to its Board of Directors.  
Mr. Pfeffer currently serves as the Corporate Vice President and
Chief Financial Officer of MannKind Corporation, a United States
based biopharmaceutical company with a market capitalization of
approximately US$1.8 billion focused on the discovery, development
and commercialization of therapeutic products for patients with
diseases such as diabetes. In addition, Mr. Pfeffer has gained
considerable experience throughout his career in financial management
roles at a number of other public companies in the pharmaceutical
industry. Mr. Pfeffer has also served on the boards and advisory
committees of the Biotechnology Industry Organization and the
American Institute of Certified Public Accountants.   
"We are pleased to welcome Mr. Pfeffer to Trimel's Board of
Directors", commented Bruce D. Brydon, Chairman of the Board. "Mr.
Pfeffer will provide Trimel's Board with strengthened insight as it
pertains to the United States marketplace. Mr. Pfeffer's experience
in finance, investor relations and combination drug device product
development represents a significant asset to Trimel as we move
forward in the building of our business."  
About Trimel  
Trimel is a specialty pharmaceutical company actively developing
medications for male hypogonadism, female sexual dysfunction and
various respiratory disorders. A New Drug Application for
CompleoTRT(TM), a product utilizing Trimel's licensed bioadhesive
intranasal gel technology, has been filed with the United States Food
and Drug Administration for regulatory approval in the United States.
For more information, please visit 
Contact: Kenneth G. Howling
Chief Financial Officer
(416) 679-0536
Press spacebar to pause and continue. Press esc to stop.